(NASDAQ: CRON) Cronos Group's forecast annual revenue growth rate of 33.06% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.89%.
Cronos Group's revenue in 2025 is $124,589,000.On average, 1 Wall Street analysts forecast CRON's revenue for 2025 to be $56,926,389,402, with the lowest CRON revenue forecast at $56,926,389,402, and the highest CRON revenue forecast at $56,926,389,402.
In 2026, CRON is forecast to generate $85,023,436,033 in revenue, with the lowest revenue forecast at $85,023,436,033 and the highest revenue forecast at $85,023,436,033.